COPD supplement study halted before it began
NCT ID NCT05130294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a salmon oil supplement called Cardio® could reduce inflammation and lower heart disease risk in people with chronic obstructive pulmonary disease (COPD). It planned to enroll adults with COPD who smoke or used to smoke. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hofseth Biocare ASA
Ålesund, More and Romsdal, 6003, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD